<DOC>
	<DOCNO>NCT00828347</DOCNO>
	<brief_summary>There still establish protocols maintenance therapy intravenous oral vitamin D preparation iPTH target achieve . Therefore , present study compare efficacy two maintenance therapy protocol , i.e. , oral administration alfacalcidol ( oral vitamin D preparation ) dose 1.0 ug/day ( higher-dose group ) dose 0.25 ug/day ( lower-dose group ) , patient secondary hyperparathyroidism respond initial maxacalcitol therapy , result control iPTH &lt; 150 pg/mL .</brief_summary>
	<brief_title>Maintenance Vitamin D Therapy Secondary Hyperparathyroidism ( 2HPT )</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) cause various bone mineral disorder , recently name CKD mineral bone disorder ( CKD-MBD ) . CKD-MBD present spectrum skeletal abnormality range high bone turnover state osteitis fibrosa , see SHPT , state low bone turnover , include osteomalacia adynamic bone disease . This disease increase risk cardiovascular disease mortality , also increase risk fracture . Therefore , important correct serum inorganic phosphorus ( Pi ) , calcium ( Ca ) parathyroid hormone ( PTH ) level dialysis patient , achieve appropriate bone turnover improve mortality . The Kidney Disease Outcomes Quality Initiative ( K/DOQI ) guideline recommend target range iPTH level vitamin D therapy set 150-300 pg/mL . In Japan , mortality risk significantly low group patient iPTH level &lt; 120 pg/mL standard group set 180 pg/mL &lt; iPTH &lt; 360 pg/mL , low group patient 60 pg/mL &lt; iPTH &lt; 120 pg/mL . Based finding , Japanese guideline recommend target range iPTH set 60-180 pg/mL . The efficacy various oral intravenous vitamin D preparation treat SHPT hemodialysis patient report . oral intravenous vitamin D pulse therapy clinically apply , especially patient severe SHPT . Up , effectiveness oral daily alfacalcidol SHPT confirm dose 0.25-0.5 μg /day ( average 0.364μg /day ) , 0.5 μg /day , 1.0 μg /day . The effective dose OCT also verify , furthermore , also report intravenous vitamin D effective oral vitamin D suppress PTH secretion . Accordingly , present intravenous vitamin D therapy standard treatment SHPT , establish protocol regard dosage administration . However , protocol establish maintenance therapy use intravenous oral vitamin D preparation control iPTH target range achieve . Therefore , present study compare efficacy two maintenance therapy protocols patient SHPT respond initial OCT therapy , result control iPTH &lt; 150pg/mL . One oral administration alfacalcidol ( oral vitamin D preparation ) dose 1.0 μg/day ( higher-dose group ) dose 0.25 μg/day ( lower-dose group ) , clinically effective dos HD patient SHPT .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Maxacalcitol</mesh_term>
	<criteria>Clinical diagnosis secondary hyperparathyroidism ( iPTH &gt; 200 pg/mL &lt; 500 pg/mL ) Serum Ca &lt; 11.0 mg/dL , serum P &lt; 7.0 mg/dL . At least one year regular hemodialysis therapy Patients history hypersensitivity ingredient maxacalcitol Patients receive parathyroidectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>